FealtySign in
Promise-keeping streak5 kept in a rowguidance & buyback

Pfizer Inc.

(PFE)

CIK 78003 · SEC filings only

Not gradedDividend record
shown as history
company entity
20 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

20 declarations · 2 raised · 8 held · 0 cut

  1. INITIATED$0.8600/shperiod ended 2026-06-28Filing ↗
  2. INITIATED$0.8600/shperiod ended 2025-06-29Filing ↗
  3. INITIATED$0.8400/shperiod ended 2024-06-30Filing ↗
  4. INITIATED$0.8200/shperiod ended 2023-07-02Filing ↗
  5. NOTED$0.4000/shperiod ended 2022-10-02Filing ↗
  6. INITIATED$0.8000/shperiod ended 2022-07-03Filing ↗
  7. NOTED$0.3900/shperiod ended 2021-10-03Filing ↗
  8. INITIATED$0.7800/shperiod ended 2021-07-04Filing ↗
  9. HELD$0.3800/shperiod ended 2020-09-24Filing ↗
  10. HELD$0.3800/shperiod ended 2020-06-25Filing ↗
  11. HELD$0.3800/shperiod ended 2020-04-23Filing ↗
  12. RAISED$0.3800/shperiod ended 2019-12-13Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
A+Guidance record
grade
company entity
5 resolved promises

Sector median (Life Sciences): B across 7 graded companies

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance by basis

6 of 11 guidance figures that were graded or dropped for basis could not be graded on the same basis (55%). Guidance marked “not judged” is in neither number.

Guidance typeSaidGradedDroppedOther
Revenue · basis not stated255020
EPS · non-GAAPcannot be graded260620

Said counts every revenue and EPS guidance figure on record. Dropped counts figures whose period was reported but which have no comparable GAAP actual in SEC XBRL. Other covers open, superseded, withdrawn and otherwise unresolved figures. The coverage note below counts every figure shown but not graded, including figures whose period has not been reported, so it can be larger.

How the site-wide rate is measured

Compare across companies

Guidance shown, not graded (27)

We show what was said — with its source filing — but never score it. The line under each statement says why.

  1. eps guidance fy · Aug 4, 2026
    Reaffirms full-year 2026 Adjusted (3) diluted EPS guidance (2) in a range of $2.80 to $3.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · May 5, 2026
    Adjusted (4) Diluted EPS in a Range of $2.80 to $3.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Feb 3, 2026
    Adjusted (3) diluted EPS guidance (1) in a range of $2.80 to $3.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Nov 4, 2025
    Raises and narrows Adjusted (2) diluted EPS guidance (1) to a range of $3.00 to $3.15
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Aug 5, 2025
    Raises Full-Year 2025 Adjusted (2) Diluted EPS Guidance (1) by $0.10 to a Range of $2.90 to $3.10
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Apr 29, 2025
    Adjusted (3) Diluted EPS in a Range of $2.80 to $3.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Feb 4, 2025
    Adjusted (3) Diluted EPS in a Range of $2.80 to $3.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Oct 29, 2024
    raises Adjusted (2) diluted EPS guidance by $0.30 at the midpoint to $2.75 to $2.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. eps guidance fy · Jul 30, 2024
    raises Adjusted (2) diluted EPS guidance by $0.30 at the midpoint to $2.45 to $2.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · May 1, 2024
    Raises Adjusted (3) Diluted EPS Guidance to $2.15 to $2.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · Jan 30, 2024
    2024 Adjusted (3) diluted EPS is anticipated to be in a range of $2.05 to $2.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · Oct 31, 2023
    Adjusted (3) Diluted EPS* $1.45 to $1.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Oct 13, 2023
    the company now expects full-year 2023 Adjusted (2) diluted EPS to be in the range of $1.45 to $1.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Aug 1, 2023
    maintaining its outlook for Adjusted diluted EPS (3) of $3.25 to $3.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · May 2, 2023
    Adjusted (3) Diluted EPS* $3.25 to $3.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · Jan 31, 2023
    Adjusted Diluted EPS (3) Guidance of $3.25 to $3.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Nov 1, 2022
    Raises and Narrows Full-Year 2022 Adjusted Diluted EPS (3) Guidance from $6.30 to $6.45 to $6.40 to $6.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance fy · Jul 28, 2022
    Range of $6.30 to $6.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. eps guidance fy · May 3, 2022
    Full-Year 2022 Financial Guidance (4) for Adjusted Diluted EPS (3) Revised to a Range of $6.25 to $6.45
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance fy · Feb 8, 2022
    Adjusted Diluted EPS (3) $6.35 to $6.55
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  21. eps guidance fy · Nov 2, 2021
    Adjusted Diluted EPS (3) $2.60 to $2.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  22. eps guidance fy · Nov 2, 2021
    Adjusted Diluted EPS (3) $4.13 to $4.18
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  23. revenue guidance fy · Nov 2, 2021
    Revenues $45.0 to $46.0 billion
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  24. eps guidance fy · Jul 28, 2021
    Adjusted Diluted EPS (3) $3.95 to $4.05
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  25. eps guidance fy · May 4, 2021
    Adjusted Diluted EPS (2) $3.55 to $3.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  26. eps guidance fy · Feb 2, 2021
    Adjusted Diluted EPS (2) $3.10 to $3.20
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  27. eps guidance fy · Jul 29, 2019
    Adjusted Diluted EPS (2) $2.76 to $2.86
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (1) · 18 superseded

Open · revenue guidance fy

Raises full-year 2026 Revenue guidance (2) by $500 million at the midpoint to a range of $60.5 to $62.5 billion

resolves in ~155 daysreceipt (opens in a new tab)
Superseded · revenue guidance fy

Pfizer raises full-year 2024 revenue guidance by $1 billion at the midpoint to a range of $59.5 to $62.5 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Reaffirms Full-Year 2022 Financial Guidance (4) for Revenues of $98.0 to $102.0 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Reaffirms All Components of Full-Year 2025 Financial Guidance (1) , including Revenues in a Range of $61.0 to $64.0 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Reaffirms full-year 2026 Revenue guidance in a range of $59.5 to $62.5 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Reaffirms Full-Year 2025 Revenue Guidance (1) in a Range of $61.0 to $64.0 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

The company narrowed its 2023 revenue guidance (4) range to $67 to $70 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Provides Full-Year 2023 Revenue Guidance (4) of $67.0 to $71.0 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Pfizer Reaffirms Revenue Guidance of $98.0 to $102.0 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Revenues $59.4 to $61.4 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Revenues $98.0 to $102.0 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

The company still expects full-year 2024 revenues to be in the range of $58.5 to $61.5 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Revenues* $67.0 to $71.0 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Pfizer expects full-year 2024 revenues (2) to be in the range of $58.5 to $61.5 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Revenues $70.5 to $72.5 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Pfizer also announced that it now anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Revenues $78.0 to $80.0 billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Revenues in a Range of $59.5 to $62.5 Billion

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Reaffirms All Components of Full-Year 2025 Financial Guidance (5) , including Revenues in a Range of $61.0 to $64.0 Billion

revised by a later guidancereceipt (opens in a new tab)

Credibility timeline

IN LINE · Feb 24, 2022IN LINE · Feb 23, 2023IN LINE · Feb 22, 2024IN LINE · Feb 27, 2025IN LINE · Feb 26, 2026
20222026
Timeline as a list
  • Feb 24, 2022IN LINERevenues $81.0 to $82.0 billion
  • Feb 23, 2023IN LINERaises Lower End of Full-Year 2022 Revenue Guidance (4) to a Range of $99.5 to $102.0 Billion
  • Feb 22, 2024IN LINERevenues* $58.0 to $61.0 billion
  • Feb 27, 2025IN LINEPfizer raises full-year 2024 revenue guidance by $1.5 billion at the midpoint to a range of $61.0 to $64.0 billion
  • Feb 26, 2026IN LINEReaffirms full-year 2025 Revenue guidance of $61.0 to $64.0 billion.
5 resolved guidance promises · 27 not graded (no comparable reported figure) · resolver resolver-v5 · score score-v1. Every verdict links to its source filing. Full methodology →